SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-24-018986
Filing Date
2024-04-29
Accepted
2024-04-29 16:06:52
Documents
21
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A itci-20240429.htm   iXBRL DEF 14A 1237083
3 itci-20240429_g1.jpg GRAPHIC 6927
4 itci-20240429_g10.jpg GRAPHIC 330269
5 itci-20240429_g2.jpg GRAPHIC 4366
6 itci-20240429_g3.jpg GRAPHIC 5189
7 itci-20240429_g4.jpg GRAPHIC 149255
8 itci-20240429_g5.jpg GRAPHIC 44387
9 itci-20240429_g6.jpg GRAPHIC 127103
10 itci-20240429_g7.jpg GRAPHIC 98343
11 itci-20240429_g8.jpg GRAPHIC 122718
12 itci-20240429_g9.jpg GRAPHIC 938958
  Complete submission text file 0001628280-24-018986.txt   6102792

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT itci-20240429.xsd EX-101.SCH 952
24 EXTRACTED XBRL INSTANCE DOCUMENT itci-20240429_htm.xml XML 150179
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36274 | Film No.: 24890653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)